Biomea Fusion, Inc. (BMEA) vs Cellectis S.A. (CLLS)

Biomea Fusion, Inc. and Cellectis S.A. are both Biotechnology companies. Biomea Fusion, Inc. and Cellectis S.A. are of similar size ($108.0M and $103.4M). Biomea Fusion, Inc. has the higher net margin (0.00% vs −102.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Biomea Fusion, Inc. leads on 8 and Cellectis S.A. on 5.

Valuation

Metric BMEA CLLS Biotechnology median
P/E n/m n/m 7.88
P/S n/m 2.32 11.47
P/B 7.87 3.60 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 0.86 10.73
Earnings yield (21.97%) (44.50%) (28.84%)
Free cash flow yield (49.11%) (31.23%) (23.03%)

Profitability

Metric BMEA CLLS Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (90.88%) 0.00%
Net margin 0.00% (102.34%) 0.00%
Free cash flow margin 0.00% (68.63%) 0.00%
Return on equity (164.14%) (94.54%) (57.72%)
Return on assets (59.14%) (21.02%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BMEA CLLS Biotechnology median
Revenue growth (TTM) — 0.61% 5.64%
EPS growth (last fiscal year) 69.19% (63.41%) —
Revenue growth, 5-year CAGR — (0.70%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BMEA CLLS Biotechnology median
Debt to equity 0.00 1.79 0.00
Current ratio 3.48 1.37 4.73
Net debt to EBITDA 0.68 9.54 0.96

Dividend

Metric BMEA CLLS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BMEA CLLS Biotechnology median
Market cap 108.00m 103.43m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack